Stock Events

Stock Events

Titan Pharmaceuticals (de) 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TN72.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap9.19B
Alkermes plc develops extended-release injectable and oral products for the treatment of prevalent and chronic diseases, similar to Titan's focus on therapeutic areas.
Indivior Pharmaceuticals
INDV
Mkt Cap4.73B
Indivior PLC offers products for the treatment of opioid dependence, directly competing with Titan's Probuphine.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries Limited manufactures generic and specialty medicines, including treatments in areas that Titan Pharmaceuticals targets.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its Janssen Pharmaceuticals, Inc. subsidiary, competes in the pharmaceuticals sector, including areas of interest to Titan.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. provides healthcare solutions that include pharmaceutical products in therapeutic areas that overlap with Titan's interests.
Pfizer
PFE
Mkt Cap138.61B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including those for treatments in areas Titan Pharmaceuticals is focused on.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie Inc. researches and develops pharmaceutical products, competing in therapeutic areas similar to those targeted by Titan Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol-Myers Squibb Company discovers, develops, and delivers innovative medicines that address serious diseases, in competition with Titan's product range.
Novartis
NVS
Mkt Cap305.1B
Novartis AG focuses on patented medicines for a range of diseases, some of which are also targeted by Titan Pharmaceuticals.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline plc engages in the creation and discovery of pharmaceutical products, including in areas that compete with Titan Pharmaceuticals' interests.

About

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Show more...
CEO
Mr. Weei Jye Chay
Employees
4
Country
United States
ISIN
US8883145075

Listings

MU
DE
TN72.MU
STU
DE
TN71.STU
STU
DE
TN72.STU

0 Comments

Share your thoughts

FAQ

What is Titan Pharmaceuticals (de) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Titan Pharmaceuticals (de) stocks are traded under the ticker TN72.MU.
How many employees does Titan Pharmaceuticals (de) have?▼
As of July 09, 2026, the company has 4 employees.
In which sector is Titan Pharmaceuticals (de) located?▼
Titan Pharmaceuticals (de) operates in the Health & Wellness sector.
When did Titan Pharmaceuticals (de) complete a stock split?▼
Titan Pharmaceuticals (de) has not had any recent stock splits.
Where is Titan Pharmaceuticals (de) headquartered?▼
Titan Pharmaceuticals (de) is headquartered in New York, United States.